1. Introduction {#sec1-cancers-12-00292}
===============

*FANCM*, the Fanconi anemia (FA) complementation group M gene (OMIM609644), was originally described as one of the members of the FA molecular pathway \[[@B1-cancers-12-00292]\] that is primarily responsible for the repair of the DNA inter-strand crosslinks through homologous recombination. FA is a recessive DNA repair disease characterized by bone marrow failure, congenital malformations, chromosome fragility, and cancer. Although *FANCM* is part of the core complex in the FA pathway, accumulating evidence indicates that protein truncating variants (PTVs) in this gene are not causative of FA. Recently, eight individuals who were not diagnosed with FA were found to harbor bi-allelic *FANCM* PTVs. Three individuals developed early-onset cancers including lymphoblastic leukemia and squamous cancers \[[@B2-cancers-12-00292]\]. In addition, five carriers of homozygous *FANCM* PTVs were identified among females diagnosed with breast cancer, two of which were diagnosed with early onset disease \[[@B3-cancers-12-00292]\]. Hence, it seems that bi-allelic *FANCM* PTVs cause cancer predisposition with a greater risk for early onset development.

In the last years, results from case-control studies have indicated that mono-allelic *FANCM* PTVs are breast cancer risk factors. The c.5101C \> T (p.Gln1701\*, rs147021911) is frequent in the Finnish population with carrier frequency = 0.0162 versus 0.00168 in non-Finnish Europeans (NFE), as reported in gnomAD v2.1.1 (<https://gnomad.broadinstitute.org/>; \[[@B4-cancers-12-00292]\]). In the Finnish population, p.Gln1701\* was found to be associated with breast cancer risk with an odds ratio (OR) of 1.86 and with greater effects in familial cases, and for estrogen receptor-negative (ER-negative) and triple-negative breast cancer (TNBC) subtypes \[[@B5-cancers-12-00292]\]. This variant was later found to be also associated with breast cancer survival and treatment outcome \[[@B6-cancers-12-00292]\]. A second *FANCM* PTV, the c.5791C \> T (p.Gly1906Alafs12\*, rs144567652), which is annotated and hereafter referred to as p.Arg1931\*, showed association with breast cancer risk in familial cases with OR = 3.93 \[[@B7-cancers-12-00292]\]. This PTV was later found to also be associated with risk for TNBC in Finnish cases with OR = 5.14 \[[@B8-cancers-12-00292]\]. A sequencing analysis of the entire *FANCM* coding region showed an excess of a third common PTV, the c.1972C \> T (p.Arg658\*, rs368728266), in German breast cancer cases versus controls, and confirmed that *FANCM* PTVs have a particularly high risk (OR = 3.75) for TNBC \[[@B9-cancers-12-00292]\]. We recently tested p.Arg658\*, p.Gln1701\*, and p.Arg1931\* in 67,112 European breast cancer cases and 53,766 controls. In these analyses, we observed that p.Arg658\* was associated with increased risk of ER-negative disease and TNBC with ORs of  2.44 and  3.79, respectively, and that p.Arg1931\* was associated with the risk of ER-negative breast cancer with an OR of 1.96 \[[@B10-cancers-12-00292]\].

*BRCA1*, *BRCA2*, and *PALB2* are established breast cancer predisposition genes conferring high risk especially for ER-negative disease and TNBC. Similarly to other genes such as *BARD1*, *RAD51D*, *BRIP1*, and *RAD51C* \[[@B11-cancers-12-00292]\], *FANCM* is emerging as a breast cancer predisposing factor conferring a greater risk specifically for these breast cancer subtypes. However, the spectrum of *FANCM* PTVs in Europe has never been investigated. Through a project call addressed to ENIGMA consortium collaborators \[[@B12-cancers-12-00292]\], we collected data from European female breast cancer probands who were subjected to the sequencing of the *FANCM* coding region, resulting as carriers of a *FANCM* PTV. This study describes the spectrum of *FANCM* PTVs in this cohort of European breast cancer cases.

2. Results and Discussion {#sec2-cancers-12-00292}
=========================

The 114 European breast cancer probands included in this study carried 27 different *FANCM* PTVs. Four, namely c.1491dupA (p.Gln498Thrfs\*7, rs797045117), p.Arg658\*, p.Gln1701\*, and p.Arg1931\*, were each identified in at least 8 probands and were classified as "common *FANCM* PTVs". The remaining 23 variants were unique or were found in not more than three probands and were classified as "rare *FANCM* PTVs". Additional data on common and rare *FANCM* PTVs were derived from previously published studies based on *FANCM* sequencing of German breast cancer probands \[[@B9-cancers-12-00292],[@B13-cancers-12-00292]\]. Altogether, these and our data allowed us to show the geographic distribution of the four common PTVs and the rare PTVs combined in a cohort of breast cancer probands ([Figure 1](#cancers-12-00292-f001){ref-type="fig"}).

Of the 114 breast cancer probands, 86 (75.4%) carried one of the four common *FANCM* PTVs ([Table 1](#cancers-12-00292-t001){ref-type="table"}). Of these 86 probands, 8 (9.3%), carried the p.Gln498Thrfs\*7, 13 (15.1%) the p.Arg658\*, 38 (44.2%) the p.Gln1701\*, and 27 (31.4%) carried the p.Arg1931\*. We observed that the relative frequency of the two most common PTVs, p.Gln1701\* and p.Arg1931\*, differ with respect to the country of origin of carriers. The p.Gln1701\* is the most common PTV in Northern Europe while it has a lower relative frequency in Southern Europe. An opposite frequency gradient along the North--South axis appeared to exist for p.Arg1931\*, which is the most common PTV in Southern Europe but more rare in Northern Europe. Consistently, in Central Europe, p.Gln1701\* and p.Arg1931\* are both common with similar relative frequencies. The relative frequencies of the *FANCM*:p.Arg658\*, the third most common *FANCM* PTV, suggest that this variant has the highest frequency in Central Europe, is present in Southern Europe, and seems to be absent or very rare in Scandinavia. The fourth common *FANCM* PTV p.Gln498Thrfs\*7 was identified in 6 of the 7 probands from Lithuania, suggesting it is a founder variant from this specific geographic area ([Table 1](#cancers-12-00292-t001){ref-type="table"}, [Figure 1](#cancers-12-00292-f001){ref-type="fig"}).

The high relative frequency of *FANCM*:p.Gln498Thrfs\*7 observed in Lithuania could indicate a founder effect in this relatively homogenous Baltic population. Similarly, haplotype analyses previously conducted in this population found a strong founder effect for several recurrent pathogenic variants in the high-risk predisposition genes *BRCA1* and *BRCA2* \[[@B14-cancers-12-00292],[@B15-cancers-12-00292]\]. Calculations from haplotype analysis and paleo-demographic data indicate that a bottleneck phenomenon occurring approximately in the 4th--5th century AD in the Lithuanian region could have contributed to decreased genetic diversity and subsequent expansion of specific alleles \[[@B14-cancers-12-00292]\].

We compared the geographic distribution of the four common PTVs observed in our study cohort with that reported in the gnomAD database v2.1.1 \[[@B4-cancers-12-00292]\]. In gnomAD, 630 European individuals carried one of the p.Gln498Thrfs\*7, p.Arg658\*, p.Gln1701\* or p.Arg1931\* PTVs with relative proportions of 3.2% (20/630), 3.3% (21/630), 54.0% (340/630), and 39.5% (249/630), respectively. About half of the p.Gln498Thrfs\*7 gnomAD carriers (9/20) were from Estonia, confirming that this variant has a specific origin in the Baltic countries. In gnomAD, p.Arg658\* was prevalently found in NFE with the higher frequency of the carries (8/21) found in North-western Europeans and only one carrier found among Southern Europeans, which is similar to what we observed. Having being found in 340 gnomAD individuals, *FANCM*:p.Gln1701\* is by far the most common PTV in Europe. As mentioned before, p.Gln1701\* was particularly frequent in Finland and was observed more frequently in North-western than Southern Europeans, which is consistent with our data. *FANCM*:p.Arg1931\* was the second most common *FANCM* PTV in Europe and the most common *FANCM* PTV in Southern Europeans in the gnomAD dataset. However, this variant was reported to be the most common also in North-western Europeans, not confirming the South--North frequency gradient observed in our cohort.

Of the 114 breast cancer probands, 29 (25.4%) carried one of the 23 rare *FANCM* PTVs ([Table 2](#cancers-12-00292-t002){ref-type="table"}). Interestingly, a proband from the Czech Republic was a bi-allelic carrier of *FANCM* PTVs having inherited the rare p.Arg1030\* variant from the mother, and the common p.Arg658\* variant from the paternal side of the family ([Table 1](#cancers-12-00292-t001){ref-type="table"} and [Table 2](#cancers-12-00292-t002){ref-type="table"}). This carrier was diagnosed with breast cancer at a young age (28 years), which is consistent with published data showing that females with bi-allelic *FANCM* PTV may develop early onset disease \[[@B3-cancers-12-00292]\]. Eight of the 23 rare PTVs were annotated in the public ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), LOVD (<https://www.lovd.nl/>), or gnomAD databases and 15 were novel. Of the 23 rare PTVs, 19 were unique; two, p.Arg754\* and p.Glu774\*, were found in three probands; and two, p.Lys1615\* and p.Thr1923Profs\*2, in two probands. Given these low frequencies, we could not speculate on the origins or the geographic distribution of any of the rare *FANCM* PTVs. Considering the numbers of carriers of common PTVs and rare PTVs in each country, we observed that in Spain and France, there was an apparent excess of carriers of rare PTVs. On the contrary, in Sweden and Lithuania, no carriers of rare PTVs were found ([Figure 1](#cancers-12-00292-f001){ref-type="fig"}).

3. Materials and Methods {#sec3-cancers-12-00292}
========================

The individuals included in our analysis were contributed by ENIGMA consortium collaborators \[[@B12-cancers-12-00292]\] interested in studying the effect/role of *FANCM* on breast cancer predisposition. They were originally ascertained at several Centers or National Studies and considered eligible for mutation sequencing analysis of breast and/or ovarian cancer predisposing genes in the frame of diagnostic or research purposes. In general, the ascertainment criteria for mutation testing were based on the presence of family history for breast or ovarian cancer, and on the early onset or specific clinical subtype of breast cancer. In the present study, we included 114 probands who received (i) a diagnosis of breast cancer, (ii) tested negative for *BRCA1* or *BRCA2* pathogenic variants, (iii) underwent complete sequencing of the *FANCM* coding region, resulting as a carrier of a PTV. Unfortunately, it was not possible to retrieve the number of probands that were originally subjected to mutation sequencing analysis at each participating Center or National Study. The 114 carriers of *FANCM* PTVs were ascertained in 20 Centers or National Studies from 13 European countries ([Table S1](#app1-cancers-12-00292){ref-type="app"}) including Czech Republic (20, 17.5%), Denmark (4, 3.5%), Finland (4, 3.5%), France (15, 13.2%), Greece (6, 5.3%), Hungary (2, 1.8%), Italy (3, 2.6%), Lithuania (7, 6.1%), Macedonia (2, 1.8%), Poland (3, 2.6%), Portugal (3, 2.6%), Spain (15, 11.4%), and Sweden (32, 28.1%). Some of these *FANCM* PTVs carriers were described in studies previously published, as indicated ([Table S1](#app1-cancers-12-00292){ref-type="app"}). Of the 114 probands, 58 (50.9%) were ER-positive, 27 (23.7%) were ER-negative, and 80 (70.2%) had a positive family history of breast or ovarian cancer. The mean age at breast cancer diagnosis was 46.7 years (min = 21, max = 85). All the 114 probands provided written informed consent for their data to be used for research purposes or specifically agreed to be tested for new variants in potential breast cancer associated genes. The participation of all the Centers or National Studies in the present work ([Table S1](#app1-cancers-12-00292){ref-type="app"}) was approved by their ethic committees. Specifically, these are the Ethics Committee of the General University Hospital in Prague (Approval code 87/14); Ethics Committee of Carlos III Institute of Health in Madrid (CEI PI 06_2013-v2); by the appropriate Advisory Committee on the Treatment of Health Research Information (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale (CCPPRB) Ile-de-France III) and by the National Data Protection authority; Ethics Committee of Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT 7/15); Ethics Committee of the Capital Region of Denmark (H-4-2010-050); Ethics Committee of Hospital District of Helsinki and Uusimaa (HUS/1597/2016); Ethical Sub-Committee on Medicine, Pharmacy, Veterinary and Dental Medicine, Macedonian Academy of Sciences and Arts (09-1047/1 from 20/04/2016); IPO (Instituto Português de Oncologia) Porto institutional review board (nr. 219-019); Comité Territorial de Ética de la Investigación de Santiago -Lugo, Conselleria de Sanidade, Xunta de Galicia (2018/200); Ethics Committee of the Area Vasta Romagna e I.R.S.T (CEAV, 1727/2012 I.5/43); Provincial Ethics Committee (209/16) and the Modena Hospital (3387); Ethics Committee of University of Rzeszow, Poland (resolution no. 9/06/2015), University of Melbourne Human Research Ethics Committee, Melbourne, Australia; National Scientific and Ethics Committee (ETT-TUKEB), 20998-0/2010-1018EKU (845/PI/010); IDIBELL (Institut d'Investigacio Biomedica de Bellvitge, Barcelona) Ethics Committee PR278/19; Lithuanian Bioethics Committee (LT-HCCA-003 protocol), Vilnius Regional Ethics Committee (Nr. 58200-12-27(1-61); Ethics Committee of Lund, Sweden (Dnr 2011/349 and 2011/652); Bioethics Committee of NSCR (National Centre of Scientific Research) Demokritos (BcncSrD-240/eHΔ/11.3, updated on 29 June 2015).

4. Conclusions {#sec4-cancers-12-00292}
==============

We described the geographic distribution and relative prevalence of 27 different *FANCM* PTVs detected in 114 female European breast cancer probands with no pathogenic variants in *BRCA1* or *BRCA2* genes. As far as we know, this is the largest available collection of breast cancer probands carrying *FANCM* PTVs. In our study-cohort, we found that the *FANCM*: p.Gln1701\* had high relative frequency in Northern Europe and low relative frequency in Southern Europe, whereas p.Arg1931\* was the most common PTV in Southern Europe and less common in Northern Europe. The p.Arg658\* had higher frequency in Central Europe, while p.Gln498Thrfs\*7 is probably a founder variant from Lithuania. Fifteen of the 27 PTVs described are novel, including one found in three probands, and one found in two probands. Further data are warranted to provide an extensive spectrum of *FANCM* PTVs in Europe.
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###### 

Eighty-six breast cancer probands who carry one of the four common *FANCM* PTVs.

  Center/Study                                                                 Country of Origin   PTV                Age at BC Diagnosis   ER-Status   BC/OC Family History
  ---------------------------------------------------------------------------- ------------------- ------------------ --------------------- ----------- ----------------------
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg658\*         53                    ER-pos      yes
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg658\*         85                    NA          no
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg658\*         35                    NA          yes
  CZECANCA-Gennet, Prague                                                      Czech Republic      p.Arg658\*         66                    ER-pos      yes
  CZECANCA-GHC, Prague                                                         Czech Republic      p.Arg658\* (\#)    28                    ER-pos      yes
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Gln1701\*        51                    ER-neg      yes
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Gln1701\*        36                    ER-pos      no
  CZECANCA-Gennet, Prague                                                      Czech Republic      p.Gln1701\*        40                    ER-neg      no
  CZECANCA-Gennet, Prague                                                      Czech Republic      p.Gln1701\*        43                    NA          no
  CZECANCA-GHC, Prague                                                         Czech Republic      p.Gln1701\*        45                    ER-pos      yes
  CZECANCA-GHC, Prague                                                         Czech Republic      p.Gln1701\*        44                    ER-pos      no
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg1931\*        41                    ER-neg      yes
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg1931\*        46                    ER-pos      no
  CZECANCA-Charles University, Prague                                          Czech Republic      p.Arg1931\*        44                    ER-pos      yes
  CZECANCA-GHC, Prague                                                         Czech Republic      p.Arg1931\*        63                    NA          no
  Copenhagen Breast Cancer Study                                               Denmark             p.Gln1701\*        58                    ER-neg      yes
  Copenhagen Breast Cancer Study                                               Denmark             p.Gln1701\*        50                    ER-pos      no
  Copenhagen Breast Cancer Study                                               Denmark             p.Arg1931\*        27                    ER-pos      yes
  Helsinki Breast Cancer Study                                                 Finland             p.Gln1701\*        46                    ER-pos      yes
  Helsinki Breast Cancer Study                                                 Finland             p.Gln1701\*        43                    ER-pos      yes
  Helsinki Breast Cancer Study                                                 Finland             p.Arg1931\*        64                    ER-pos      yes
  GENE SISters                                                                 France              p.Gln1701\*        44                    ER-pos      yes
  Institut Curie, Paris                                                        France              p.Gln1701\*        63                    NA          yes
  GENE SISters                                                                 France              p.Arg1931\*        54                    ER-pos      yes
  GENE SISters                                                                 France              p.Arg1931\*        39                    ER-pos      yes
  GENE SISters                                                                 France              p.Arg1931\*        65                    ER-pos      yes
  GENE SISters                                                                 France              p.Arg1931\*        45                    ER-pos      yes
  GENE SISters                                                                 France              p.Arg1931\*        43                    NA          yes
  Institut Curie, Paris                                                        France              p.Arg1931\*        48                    NA          yes
  National Center for Scientific Research-Demokritos, Athens                   Greece              p.Arg658\*         33                    ER-neg      no
  National Center For Scientific Research-Demokritos, Athens                   Greece              p.Gln1701\*        61                    ER-pos      yes
  National Center For Scientific Research-Demokritos, Athens                   Greece              p.Arg1931\*        63                    ER-neg      yes
  National Center For Scientific Research-Demokritos, Athens                   Greece              p.Arg1931\*        42, 45                ER-pos      no
  Hungarian Breast and Ovarian Cancer Study                                    Hungary             p.Arg658\*         44                    ER-pos      yes
  Hungarian Breast and Ovarian Cancer Study                                    Hungary             p.Arg658\*         35                    ER-pos      yes
  Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan                        Italy               p.Arg1931\*        49                    NA          yes
  Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola   Italy               p.Arg1931\*        32                    ER-pos      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   31                    ER-neg      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   35                    ER-neg      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   46                    ER-pos      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   39                    ER-pos      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   58                    ER-pos      yes
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Gln498Thrfs\*7   75                    ER-pos      no
  Vilnius University Hospital Santaros Klinikos                                Lithuania           p.Arg658\*         39                    ER-pos      no
  Macedonian Breast Cancer Study                                               Macedonia           p.Arg1931\*        65                    ER-neg      no
  Wroclaw Medical University, Wrocław                                          Poland              p.Gln498Thrfs\*7   63                    ER-neg      no
  Wroclaw Medical University, Wrocław                                          Poland              p.Gln498Thrfs\*7   52                    NA          yes
  Wroclaw Medical University, Wrocław                                          Poland              p.Arg658\*         62                    ER-pos      yes
  Portuguese Oncology Institute-Porto Breast Cancer Study                      Portugal            p.Arg658\*         29                    NA          yes
  Fundación Pública Galega Medicina Xenómica, Santiago de Compostela           Spain               p.Arg658\*         40                    ER-neg      no
  Spanish National Cancer Research Centre, Madrid                              Spain               p.Arg658\*         38                    ER-pos      yes
  Catalan Institute of Oncology, Barcelona                                     Spain               p.Arg1931\*        48                    ER-pos      yes
  Catalan Institute of Oncology, Barcelona                                     Spain               p.Arg1931\*        55                    ER-pos      yes
  Spanish National Cancer Research Centre, Madrid                              Spain               p.Arg1931\*        47                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        34                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        58                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        21                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        71                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        71                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        57                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        37                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        68                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        43                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        54                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        56                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        48                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        27                    ER-pos      no
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        42                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        60                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        44                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        57                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        32                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        46                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        49                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        36                    NA          no
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        46                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        39                    NA          no
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        28                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Gln1701\*        47                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        36                    ER-neg      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        47                    ER-neg      no
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        52                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        55                    ER-pos      yes
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        36                    ER-pos      no
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        39                    NA          yes
  Swedish Breast Cancer Study                                                  Sweden              p.Arg1931\*        56                    NA          yes

PTV, protein truncating variant; BC, breast cancer; OC, ovarian cancer; ER, estrogen receptor; pos, positive; neg, negative; NA, not available. (\#) This individual also carries the rare *FANCM*: c.3088C \> T (p.Arg1030\*) PTV and is also included in [Table 2](#cancers-12-00292-t002){ref-type="table"}.

cancers-12-00292-t002_Table 2

###### 

Twenty-nine breast cancer probands who carry one of the 23 rare *FANCM* PTVs.

  Center/Study                                                         Country of Origin   PTV                                      Annotated in Databases   Age at BC Diagnosis   ER-Status   BC/OC Family History
  -------------------------------------------------------------------- ------------------- ---------------------------------------- ------------------------ --------------------- ----------- ----------------------
  CZECANCA-AGEL, Novy Jicin                                            Czech Republic      c.1798C \> T; p.Gln600\*                 no                       37                    ER-pos      yes
  CZECANCA-Charles University, Prague                                  Czech Republic      c.3898G \> T; p.Glu1300\*                no                       37                    ER-pos      no
  CZECANCA-Charles University, Prague                                  Czech Republic      c.3979_3980delCA; p.Gln1327Valfs\*16     LOVD, gnomAD             50                    ER-pos      yes
  CZECANCA-Gennet, Prague                                              Czech Republic      c.2260C \> T; p.Arg754\*                 gnomAD                   51                    ER-neg      no
  CZECANCA-Gennet, Prague                                              Czech Republic      c.2260C \> T; p.Arg754\*                 gnomAD                   34                    ER-neg      no
  CZECANCA-GHC, Prague                                                 Czech Republic      c.3088C \> T; p.Arg1030\* (\#)           no                       28                    ER-pos      yes
  Copenhagen Breast Cancer Study                                       Denmark             c.3745_3748del; p.Thr1249Glnfs\*7        no                       50                    ER-pos      NA
  Helsinki Breast Cancer Study                                         Finland             c.4021_4022del                           no                       39                    ER-pos      yes
  GENE SISters                                                         France              c.1432C \> T; p.Arg478\*                 no                       48                    NA          yes
  GENE SISters                                                         France              c.3745dupA; p.His1248fs                  no                       63                    NA          yes
  Institut Curie, Paris                                                France              c.1868delA; p.Arg624Glufs\*46            no                       56                    ER-neg      yes
  Institut Curie, Paris                                                France              c.2260C \> T; p.Arg754\*                 gnomAD                   43                    ER-neg      yes
  Institut Curie, Paris                                                France              c.2590delG; p.Asp864Ilefs\*12            no                       64                    ER-neg      yes
  Institut Curie, Paris                                                France              c.4930C \> T; p.Arg1644\*                gnomAD                   46                    NA          yes
  Institut Curie, Paris                                                France              c.5363delCTAG; p.Ser1788Leufs\*15        no                       43                    ER-neg      no
  National Center For Scientific Research-Demokritos, Athens           Greece              c.4843A \> T; p.Lys1615\*                LOVD                     33                    NA          yes
  National Center For Scientific Research-Demokritos, Athens           Greece              c.5314_5315delTG; p.Cys1772\*            LOVD, gnomAD             47                    ER-pos      yes
  Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan                Italy               c.2354T \> G; p.Leu785\*                 no                       35                    NA          no
  Macedonian Breast Cancer Study                                       Macedonia           c.5048_5052delAAAGA; p.Lys1683Argfs\*3   gnomAD                   32                    ER-neg      no
  Portuguese Oncology Institute-Porto Breast Cancer Study              Portugal            c.2320G \> T; p.Glu774\*                 no                       42                    ER-neg      yes
  Portuguese Oncology Institute-Porto Breast Cancer Study              Portugal            c.5766_5769del; p.Thr1923Profs\*2        no                       43                    ER-neg      yes
  Catalan Institute of Oncology, Barcelona                             Spain               c.624_625delAA; p.Ile208fs               no                       23                    NA          no
  Catalan Institute of Oncology, Barcelona                             Spain               c.1303C \> T; p.Gln435\*                 no                       39                    ER-pos      yes
  Catalan Institute of Oncology, Barcelona                             Spain               c.5766_5769del; p.Thr1923Profs\*2        no                       31                    ER-pos      no
  Fundación Pública Galega Medicina Xenómica, Santiago de Compostela   Spain               c.2320G \> T; p.Glu774\*                 no                       57                    ER-neg      yes
  Fundación Pública Galega Medicina Xenómica, Santiago de Compostela   Spain               c.2586_2589delAAAA; p.Lys863Ilefs\*12    ClinVar, LOVD, gnomAD    49                    NA          yes
  Spanish National Cancer Research Centre, Madrid                      Spain               c.1196C \> G; p.Ser399\*                 ClinVar                  66                    NA          yes
  Spanish National Cancer Research Centre, Madrid                      Spain               c.2320G \> T; p.Glu774\*                 no                       40, 65                ER-pos      yes
  Spanish National Cancer Research Centre, Madrid                      Spain               c.4843A \> T; p.Lys1615\*                LOVD                     41                    NA          yes

PTV, protein truncating variant; BC, breast cancer; OC, ovarian cancer; ER, estrogen receptor; pos, positive; neg, negative; NA, not available. (\#) This individual also carries the common PTV, p.Arg658\*, and is also included in [Table 1](#cancers-12-00292-t001){ref-type="table"}.
